The blood vessels around the cornea may be the primary pathway by which the antibody-drug conjugate Blenrep (belantamab mafodotin) causes ocular adverse events, finds a case analysis published recently in JAMA Ophthalmology .

The FDA had originally granted accelerated approval of Blenrep in August 2020 as a monotherapy to treat relapsed or refractory multiple myeloma based on the DREAMM-2 endpoint of overall response rate. But in November 2022, Blenrep’s developer, GSK, announced it withdrew Blenrep from the U.S. market at the request of the FDA. Although ocular adverse events were known during clinical development of Blenrep, this was not the reason for the product’s withdrawal. The agency made the request after the DREAMM-3 phase 3 confirmatory failed to meet its endpoint of pro

See Full Page